141 related articles for article (PubMed ID: 14976048)
1. Phosphoinositide 3-kinase signaling is essential for ABL oncogene-mediated transformation of B-lineage cells.
Kharas MG; Deane JA; Wong S; O'Bosky KR; Rosenberg N; Witte ON; Fruman DA
Blood; 2004 Jun; 103(11):4268-75. PubMed ID: 14976048
[TBL] [Abstract][Full Text] [Related]
2. Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells.
Kharas MG; Janes MR; Scarfone VM; Lilly MB; Knight ZA; Shokat KM; Fruman DA
J Clin Invest; 2008 Sep; 118(9):3038-50. PubMed ID: 18704194
[TBL] [Abstract][Full Text] [Related]
3. eIF4B is a convergent target and critical effector of oncogenic Pim and PI3K/Akt/mTOR signaling pathways in Abl transformants.
Chen K; Yang J; Li J; Wang X; Chen Y; Huang S; Chen JL
Oncotarget; 2016 Mar; 7(9):10073-89. PubMed ID: 26848623
[TBL] [Abstract][Full Text] [Related]
4. Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells.
Weisberg E; Banerji L; Wright RD; Barrett R; Ray A; Moreno D; Catley L; Jiang J; Hall-Meyers E; Sauveur-Michel M; Stone R; Galinsky I; Fox E; Kung AL; Griffin JD
Blood; 2008 Apr; 111(7):3723-34. PubMed ID: 18184863
[TBL] [Abstract][Full Text] [Related]
5. Activation of the PI3K/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species.
Kim JH; Chu SC; Gramlich JL; Pride YB; Babendreier E; Chauhan D; Salgia R; Podar K; Griffin JD; Sattler M
Blood; 2005 Feb; 105(4):1717-23. PubMed ID: 15486067
[TBL] [Abstract][Full Text] [Related]
6. ABL oncogenes and phosphoinositide 3-kinase: mechanism of activation and downstream effectors.
Kharas MG; Fruman DA
Cancer Res; 2005 Mar; 65(6):2047-53. PubMed ID: 15781610
[TBL] [Abstract][Full Text] [Related]
7. Differential expression and signaling of CBL and CBL-B in BCR/ABL transformed cells.
Sattler M; Pride YB; Quinnan LR; Verma S; Malouf NA; Husson H; Salgia R; Lipkowitz S; Griffin JD
Oncogene; 2002 Feb; 21(9):1423-33. PubMed ID: 11857085
[TBL] [Abstract][Full Text] [Related]
8. BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin.
Mayerhofer M; Valent P; Sperr WR; Griffin JD; Sillaber C
Blood; 2002 Nov; 100(10):3767-75. PubMed ID: 12393646
[TBL] [Abstract][Full Text] [Related]
9. Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway.
Skorski T; Bellacosa A; Nieborowska-Skorska M; Majewski M; Martinez R; Choi JK; Trotta R; Wlodarski P; Perrotti D; Chan TO; Wasik MA; Tsichlis PN; Calabretta B
EMBO J; 1997 Oct; 16(20):6151-61. PubMed ID: 9321394
[TBL] [Abstract][Full Text] [Related]
10. Optimal B-cell proliferation requires phosphoinositide 3-kinase-dependent inactivation of FOXO transcription factors.
Yusuf I; Zhu X; Kharas MG; Chen J; Fruman DA
Blood; 2004 Aug; 104(3):784-7. PubMed ID: 15069012
[TBL] [Abstract][Full Text] [Related]
11. Critical role for Gab2 in transformation by BCR/ABL.
Sattler M; Mohi MG; Pride YB; Quinnan LR; Malouf NA; Podar K; Gesbert F; Iwasaki H; Li S; Van Etten RA; Gu H; Griffin JD; Neel BG
Cancer Cell; 2002 Jun; 1(5):479-92. PubMed ID: 12124177
[TBL] [Abstract][Full Text] [Related]
12. KLF4 suppresses transformation of pre-B cells by ABL oncogenes.
Kharas MG; Yusuf I; Scarfone VM; Yang VW; Segre JA; Huettner CS; Fruman DA
Blood; 2007 Jan; 109(2):747-55. PubMed ID: 16954505
[TBL] [Abstract][Full Text] [Related]
13. Bcr and Abl interaction: oncogenic activation of c-Abl by sequestering Bcr.
Ling X; Ma G; Sun T; Liu J; Arlinghaus RB
Cancer Res; 2003 Jan; 63(2):298-303. PubMed ID: 12543778
[TBL] [Abstract][Full Text] [Related]
14. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity.
Li S; Ilaria RL; Million RP; Daley GQ; Van Etten RA
J Exp Med; 1999 May; 189(9):1399-412. PubMed ID: 10224280
[TBL] [Abstract][Full Text] [Related]
15. EPS8 regulates proliferation, apoptosis and chemosensitivity in BCR-ABL positive cells via the BCR-ABL/PI3K/AKT/mTOR pathway.
Huang R; Liu H; Chen Y; He Y; Kang Q; Tu S; He Y; Zhou X; Wang L; Yang J; Wu A; Li Y
Oncol Rep; 2018 Jan; 39(1):119-128. PubMed ID: 29192326
[TBL] [Abstract][Full Text] [Related]
16. Mutant forms of growth factor-binding protein-2 reverse BCR-ABL-induced transformation.
Gishizky ML; Cortez D; Pendergast AM
Proc Natl Acad Sci U S A; 1995 Nov; 92(24):10889-93. PubMed ID: 7479904
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.
Koch A; Scherr M; Breyer B; Mancini A; Kardinal C; Battmer K; Eder M; Tamura T
Oncogene; 2008 Aug; 27(34):4678-89. PubMed ID: 18427551
[TBL] [Abstract][Full Text] [Related]
18. Targeting PIM kinases impairs survival of hematopoietic cells transformed by kinase inhibitor-sensitive and kinase inhibitor-resistant forms of Fms-like tyrosine kinase 3 and BCR/ABL.
Adam M; Pogacic V; Bendit M; Chappuis R; Nawijn MC; Duyster J; Fox CJ; Thompson CB; Cools J; Schwaller J
Cancer Res; 2006 Apr; 66(7):3828-35. PubMed ID: 16585210
[TBL] [Abstract][Full Text] [Related]
19. Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development.
Burchert A; Wang Y; Cai D; von Bubnoff N; Paschka P; Müller-Brüsselbach S; Ottmann OG; Duyster J; Hochhaus A; Neubauer A
Leukemia; 2005 Oct; 19(10):1774-82. PubMed ID: 16136169
[TBL] [Abstract][Full Text] [Related]
20. [Mechanism underlying tumorigenesis induced by Bcr-Abl oncogene and A-MuLV virus].
Sun Y; Chen N; Wang X; Chen JL; Ma Y
Sheng Wu Gong Cheng Xue Bao; 2018 Dec; 34(12):1943-1952. PubMed ID: 30584705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
